Retrospective analysis of 71 patients with malignant serous cavity effusions (MSE) treated with either Endostar-platinum or bevacizumab-platinum regimens revealed that bevacizumab combined with platinum yielded superior objective response rate (ORR: 56.76% vs 45.16%, P<0.050) and significantly prolonged median progression-free survival (mPFS: 13.0 vs 10.0 months, HR=0.409, 95% CI: 0.219–0.764, P=0.001) compared with Endostar-platinum. The two regimens showed comparable disease control rate (DCR), quality of life (QOL) and adverse events profiles. Multivariate analyses identified absence of pulmonary metastasis, completion of ≥3 treatment cycles, and 200 mg bevacizumab dose as independent prognostic factors for longer mPFS in MSE patients.

Hui Yang, Yuzhi Li, Bo Yang, Xiang Sun. Real-World Efficacy and Safety of Endostar-Platinum versus Bevacizumab-Platinum Intracavitary Perfusion for Serous Cavity Effusions. International Journal of Frontiers in Medicine (2026), Vol. 8, Issue 1: 22-30. https://doi.org/10.25236/IJFM.2026.080103.

[1] Barton E, Verduri A, Carter B, Hughes J, Hewitt J, Maskell NA.(2024).The association between frailty and survival in patients with pleural disease: a retrospective cohort study. BMC Pulm Med 24(1) 180. doi:10.1186/s12890-024-02981-3

[2] Zhang J, Qi Z, Ou W, Mi X, Fang Y, Zhang W, et al.(2024).Advances in the treatment of malignant ascites in China. Supportive Care in Cancer 32(2) 97. doi:10.1007/s00520-023-08299-w

[3] Gonnelli F, Hassan W, Bonifazi M, Pinelli V, Bedawi EO, Porcel JM, et al.(2024).Malignant pleural effusion: current understanding and therapeutic approach. Respir Res 25(1) 47. doi:10.1186/s12931-024-02684-7

[4] Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A.(2015).Clinical features and survival of lung cancer patients with pleural effusions. Respirology 20(4) 654-659. doi:10.1111/resp.12496

[5] Psallidas I, Kanellakis NI, Gerry S, Thézénas ML, Charles PD, Samsonova A, et al. (2018). Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. Lancet Oncol 19(7) 930-939. doi:10.1016/s1470-2045(18)30294-8

[6] Orlandi R, Cara A, Cassina EM, Degiovanni S, Libretti L, Pirondini E, et al.(2024).Malignant Pleural Effusion: Diagnosis and Treatment-Up-to-Date Perspective. Curr Oncol 31(11) 6867-6878. doi:10.3390/curroncol31110507

[7] Chen Y, Mathy NW, Lu H.(2018).The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non‑small cell lung cancer (Review). Mol Med Rep 17(6) 8019-8030. doi:10.3892/mmr.2018.8922

[8] Anakha J, Prasad YR, Pande AH.(2025).Endostatin in disease modulation: From cancer to beyond. Vascul Pharmacol 158 107459. doi:10.1016/j.vph.2024.107459

[9] [Chinese expert consensus on treatment of malignant pleural effusion (2023 Edition)]. 2023). Chinese journal of tuberculosis and respiratory diseases 46(12) 1189-1203. doi:10.3760/cma.j.cn112147-20230902-00126

[10] Zachary I.(2001). Signalling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 280(6) C1375-1386. doi:10.1152/ajpcell.2001.280.6.C1375

[11] Ribatti D.(2016). Tumour refractoriness to anti-VEGF therapy. Oncotarget 7(29) 46668-46677. doi:10.18632/oncotarget.8694

[12] Mulligan JK, Rosenzweig SA, Young MR.(2010). Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2. J Immunother 33(2) 126-135. doi:10.1097/CJI.0b013e3181b91c9c

[13] Ferrara N, Adamis AP.(2016).Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov 15(6) 385-403. doi:10.1038/nrd.2015.17

[14] Guo L, Qin X, Xue L, Yang JY, Zhang Y, Zhu S, et al.(2022). A novel form of docetaxel polymeric micelles demonstrates anti-tumor and ascites-inhibitory activities in animal models as monotherapy or in combination with anti-angiogenic agents. Front Pharmacol 13 964076. doi:10.3389/fphar.2022.964076

[15] Wang P, Jiang LZ, Xue B.(2016). Recombinant human endostatin reduces hypertrophic scar formation in the rabbit ear model through down-regulation of VEGF and TIMP-1. Afr Health Sci 16(2) 542-553. doi:10.4314/ahs.v16i2.23

[16] [Expert consensus on diagnosis and treatment of malignant pleural effusion caused by lung cancer].(2024). Chinese journal of oncology 46(1) 40-47. doi:10.3760/CMA.J.CN112152-20231130-00344.

[17] Cao DC, Liang Y, Guo Y, Wu DY, Wang NN, Li YM, et al.(2025).Oxygen-Generating Biomimetic Nano-Herb System for Synergistic Therapy & Pain Relief in Triple-Negative Breast Cancer via HIF-1α/VEGF Pathway. Int J Nanomedicine 20 7113-7132. doi:10.2147/ijn.S523754

[18] Deregulation of LIMD1-VHL-HIF-1α-VEGF pathway is associated with different stages of cervical cancer. (2025).Biochem J 482(11). doi:10.1042/bcj20170649_ret

[19] Chinese Clinical Oncology Society Expert Committee for Vascular Targeted Therapy, The Expert Group of Anti-Angiogenic Drugs for Non-Small Cell Lung Cancer of the Chinese Society of Clinical Oncology. (2020). Chinese Expert Consensus on Anti-Angiogenic Drug Therapy for Advanced Non-Small Cell Lung Cancer (2020 Edition). In chinese. Chinese Journal of Oncology. 42(12) 1063-1077. doi:10.3760/cma.j.cn112152-20200918-00836,

[20] Wang J,Pang B,Zhang J,Ren X,Han Y.(2025).Malignant pleural effusion is a negative prognostic factor for immunotherapy outcomes in non-small cell lung cancer: a single-center retrospective study. Journal of thoracic disease 17(5) 3064-3072. doi:10.21037/jtd-2024-1999

[21] Zhan Z, Wang X, Yu J, Zheng J, Zeng Y, Sun M, et al.(2022). Intraperitoneal infusion of recombinant human endostatin improves prognosis in gastric cancer ascites. Future Oncol 18(10) 1259-1271. doi:10.2217/fon-2021-0896

[22] Di W, Yue C, Ziran Z, Jie Z, Jun N, Ling D, et al.(2022).A phase II study of bevacizumab in non-squamous, non-small-cell lung cancer patients with malignant pleural effusion. Future Oncol 18(6) 669-677. doi:10.2217/fon-2021-1035

[23] Shengfang Yuan, Bu Wang, Bo Xiang, Jianqing Zhao, Zhihua Zhang, Xiulong Zhang. (2023). The clinical efficacy of bevacizumab combined with lobaplatin intrathoracic injection in the treatment of malignant pleural effusion caused by lung cancer. In chinese. Journal of Dalian Medical University. 45(4) 299-303. doi:10.11724/jdmu.2023.04.03